Thomas A. Mace

4.2k citations

64 papers · 2.6k indexed · 1 hit paper · h-index 26

Impact in

Oncology top 2%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
Immunology top 2%
- Immune cells in cancer
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses

Papers in

Immunology 27
- Phagocytosis and Immune Regulation 11
- Immune cells in cancer 8
- Immune Cell Function and Interaction 7
Oncology 27
- Pancreatic and Hepatic Oncology Research 15
- Cancer Immunotherapy and Biomarkers 12
- Cancer Cells and Metastasis 5

Co-authors: Gregory B. Lesinski Mark Bloomston Elizabeth A. Repasky Gregory Young Tanios Bekaii‐Saab Chen-Ting Lee Lingwen Zhong Amy Collins
Journals: Cancer Research (7 papers)Journal for ImmunoTherapy of Cancer (7 papers)Cancer Immunology Immunotherapy (5 papers)Clinical Cancer Research (3 papers)Scientific Reports (3 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Thomas A. Mace

61 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer 2016 · 401 citations

Peers

Countries citing papers authored by Thomas A. Mace

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Mace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Mace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Mace more than expected).

Fields of papers citing papers by Thomas A. Mace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Mace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Mace. The network helps show where Thomas A. Mace may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas A. Mace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas A. Mace Line = papers co-authored together Thomas A. Mace links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Intramuscular CMT‐167 Tumours Produce a Mild Cachexia Phenotype in C57BL/6J Mice PubMed ·王铧, Trang T. Vu, Justin Thomas, Wilhelm Schöllmann, 純子大森, Zhiliang Xie, K. Ido, Liang Zhang, Paul Gregorevic, Taisuke EZOE, Jeovanna Lowe, Jill A. Rafael‐Fortney, Samuel K. Kulp, Latha P. Ganesan, Dwight H. Owen, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps	2025	0
2	Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors Clinical Cancer Research ·Yizhen Guo, 王铧, Justin Thomas, Wilhelm Schöllmann, Samuel K. Kulp, Thomas A. Mace, Latha P. Ganesan, Dwight H. Owen, Christopher C. Coss, Mitch A. Phelps	2023	6
3	The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial Pancreatology ·Samuel Han, Darwin L. Conwell, Liang Li, 知念正人, Phil A. Hart, Zobeida Cruz‐Monserrate, Wenrui Hao, Gregory B. Lesinski, Thomas A. Mace, Tonya M. Palermo, Jami L. Saloman, Dhiraj Yadav, Santhi Swaroop Vege, Mark Topazian	2022	7
4	A Pilot Study to Assess Opportunistic Use of CT-Scan for Osteoporosis Screening in Chronic Pancreatitis Frontiers in Physiology ·Julia McNabb‐Baltar, Jonathan Fernández-González, Darwin L. Conwell, Wojciech Brochwicz Lewiński, Dhiraj Yadav, Philip Hart, Luis F. Lara, Zobeida Cruz‐Monserrate, Steven Ing, Alice Hinton, Thomas A. Mace, David Bradley, Zarine K. Shah	2022	7
5	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer Expert Review of Anticancer Therapy ·Yeoju, Wichittra Phlicharoenphon., Yizhen Guo, Christopher C. Coss, Thomas A. Mace, Jason J. Bischof, Mitch A. Phelps, Carolyn J. Presley, Dwight H. Owen	2022	9
6	CD200 promotes immunosuppression in the pancreatic tumor microenvironment Journal for ImmunoTherapy of Cancer ·Fouad Choueiry, Karishma Kripalani, Reena Shakya, K. Cho, Riley Heiman, Brooke Benner, Alice Hinton, LI Qi-ca, Bradley W. Blaser, Anne M. Noonan, Terence M. Williams, Mary Dillhoff, Darwin L. Conwell, Phil A. Hart, Zobeida Cruz‐Monserrate, Xue‐Feng Bai, William E. Carson, Thomas A. Mace	2020	61
7	Lipocalin-2 expression and function in pancreatic diseases Pancreatology ·Kristyn Gumpper, Andrew W. Dangel, Norbert Wendt, Somashekar G. Krishna, Luis F. Lara, Thomas A. Mace, Georgios I. Papachristou, Darwin L. Conwell, Phil A. Hart, Zobeida Cruz‐Monserrate	2020	16
8	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease British Journal of Cancer ·عنایت عباسی, Mohammad Y. Zaidi, Jennifer Yang, Dietmar Kottmann, Alyssa M. Krasinskas, Thomas A. Mace, 顾红义, Matthew R. Farren, 良一井部, Yiman Li, Chao Zhang, Zhengjia Chen, Gregory Young, I.N. Smorodinsky, Anton Belushenko, Shishir K. Maithel, Tanios Bekaii‐Saab, Bassel F. El‐Rayes, Gregory B. Lesinski	2020	5
9	Parkinson’s Hub: An integrated pathway for people with Parkinson's and frailty SHILAP Revista de lepidopterología ·Thomas A. Mace, WANG Kaiyong	2020	2
10	Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains PLoS ONE ·Dongju Park, Reena Shakya, Christopher S. Koivisto, Jason R. Pitarresi, Matthias Szabolcs, Raleigh D. Kladney, 冯永成, Thomas A. Mace, Thomas Ludwig	2019	7
11	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment Cancer Research ·Oksana Zharovа, Agnieszka Świdnicka‐Siergiejko, Martin Trefalt, Myrriah Chavez-Tomar, Gregory B. Lesinski, Tanios Bekaii‐Saab, Matthew R. Farren, Thomas A. Mace, Carl Schmidt, Yan Liu, Defeng Deng, Rosa F. Hwang, Liran Zhou, Todd T. Moore, Deyali Chatterjee, Huamin Wang, Xiaohong Leng, Ralph B. Arlinghaus, Craig D. Logsdon, Zobeida Cruz‐Monserrate	2017	114
12	Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo Scientific Reports ·Antônio José Dourado Filho, Mythili, Sichel, C. Eswari, Thomas A. Mace, Ming Jin, S.A. Chichghare, Ching‐Shih Chen, Mark Bloomston, Michael C. Ostrowski, Phil A. Hart, Darwin L. Conwell, Gregory B. Lesinski	2017	63
13	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities Molecular Cancer Therapeutics ·Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory Young, I.N. Smorodinsky, Anton Belushenko, Cynthia Timmers, Priyani Rajasekera, Hennita Br Ginting, Mark Bloomston, Tanios Bekaii‐Saab, Denis C. Guttridge, Gregory B. Lesinski	2016	29
14	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer Gut ·Thomas A. Mace, Reena Shakya, Jason R. Pitarresi, Benjamin Swanson, Christopher McQuinn, Shannon Loftus, Emily Nordquist, Zobeida Cruz‐Monserrate, Lianbo Yu, Gregory Young, Xiaoling Zhong, Teresa A. Zimmers, Michael C. Ostrowski, Thomas Ludwig, Mark Bloomston, Tanios Bekaii‐Saab, Gregory B. Lesinski Hit paper breakdown →	2016	401
15	Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5 Journal for ImmunoTherapy of Cancer ·Jason W.‐L. Eng, Thomas A. Mace, Rohit B. Sharma, Maxim O. Konovalenko, Peng Peng, John F. Gibbs, Prijith A. Thomas, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky, Bonnie L. Hylander	2016	12
16	Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells Cancer Prevention Research ·Gregory B. Lesinski, Patrick K. Reville, Thomas A. Mace, Gregory Young, Jennifer Ahn‐Jarvis, Jennifer M. Thomas‐Ahner, Yael Vodovotz, Zeenath Ameen, Elizabeth M. Grainger, Kenneth M. Riedl, Steven D. Schwartz, Steven K. Clinton	2015	70
17	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer Clinical Cancer Research ·Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen K. Ciombor, Sanaa Tahiri, Daniel H. Ahn, Anne M. Noonan, Miguel A. Villalona‐Calero, Tanios Bekaii‐Saab, Gregory B. Lesinski	2015	69
18	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma Clinical Cancer Research ·Douglas W. Sborov, Gerard J. Nuovo, Andrew Stiff, Thomas A. Mace, Gregory B. Lesinski, Don M. Benson, Yvonne A. Efebera, Ashley Rosko, Flavia Pichiorri, Michael R. Grever, Craig C. Hofmeister	2014	71
19	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner Cancer Research ·Thomas A. Mace, Zeenath Ameen, Amy Collins, Sylwia E. Wojcik, Markus Mair, Gregory Young, James R. Fuchs, Timothy D. Eubank, Wendy L. Frankel, Tanios Bekaii‐Saab, Mark Bloomston, Gregory B. Lesinski	2013	344
20	Pancreatic cancer-associated stellate cells OncoImmunology ·Thomas A. Mace, Mark Bloomston, Gregory B. Lesinski	2013	51

About Thomas A. Mace

Thomas A. Mace is a scholar working on Immunology, Oncology, Critical Care and Intensive Care Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 64 papers that have together received 2.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer Immunotherapy and Biomarkers (12 papers), Phagocytosis and Immune Regulation (11 papers), Pancreatitis Pathology and Treatment (10 papers), Immune cells in cancer (8 papers), Immune Cell Function and Interaction (7 papers), Cancer Cells and Metastasis (5 papers) and Virus-based gene therapy research (4 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (976 citations), Cancer Research (353 citations), Biotechnology (128 citations) and Molecular Biology (777 citations). Thomas A. Mace has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Gregory B. Lesinski, Mark Bloomston, Elizabeth A. Repasky, Gregory Young, Tanios Bekaii‐Saab, Chen-Ting Lee, Lingwen Zhong, Amy Collins, Sylwia E. Wojcik and Zeenath Ameen. Their work appears in journals such as Cancer Research, Journal for ImmunoTherapy of Cancer, Cancer Immunology Immunotherapy, Clinical Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact